Warning: The NCBI web site requires JavaScript to function. more...
EGFR/Met association regulates EGFR TKI resistance in breast cancer.
Mueller KL, Yang ZQ, Haddad R, Ethier SP, Boerner JL.
J Mol Signal. 2010 Jul 12;5:8.
Related citations
Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.
Mueller KL, Hunter LA, Ethier SP, Boerner JL.
Cancer Res. 2008 May 1;68(9):3314-22.
The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Lee SS, Kim CH, Yoo YD, Lee JC.
Mol Cancer Res. 2009 Oct;7(10):1736-43. Epub 2009 Oct 6.
Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.
Yamamoto N, Mammadova G, Song RX, Fukami Y, Sato K.
J Cell Sci. 2006 Nov 15;119(Pt 22):4623-33. Epub 2006 Oct 24.
Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S.
Clin Cancer Res. 2010 Jan 1;16(1):174-83. Epub 2009 Dec 15.
Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Irwin ME, Mueller KL, Bohin N, Ge Y, Boerner JL.
J Cell Physiol. 2011 Sep;226(9):2316-28. doi: 10.1002/jcp.22570.
Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells.
Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV.
Oncogene. 2010 May 6;29(18):2616-27. Epub 2010 Feb 15.
Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B, Chang CM, Yuan M, McKenna WG, Shu HK.
Cancer Res. 2003 Nov 1;63(21):7443-50.
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R.
Int J Mol Med. 2007 Jul;20(1):3-10. Review.
Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.
Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI.
Endocrinology. 2005 Nov;146(11):4609-18. Epub 2005 Jul 21.
Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
Fox EM, Bernaciak TM, Wen J, Weaver AM, Shupnik MA, Silva CM.
Mol Endocrinol. 2008 Aug;22(8):1781-96. Epub 2008 Jun 11.
Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Chen HJ, Mok TS, Chen ZH, Guo AL, Zhang XC, Su J, Wu YL.
Pathol Oncol Res. 2009 Dec;15(4):651-8. Epub 2009 Apr 21.
Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C, Vazquez-Martin A, López-Bonet E, Martín-Castillo B, Del Barco S, Brunet J, Menendez JA.
Int J Oncol. 2008 Dec;33(6):1165-76.
Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells.
Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL, Cheng N.
Cancer Biol Ther. 2007 Apr;6(4):561-70.
Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
Clin Cancer Res. 2009 Feb 1;15(3):907-13.
Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI.
Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):344-52.
Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells.
Das R, Mahabeleshwar GH, Kundu GC.
J Biol Chem. 2004 Mar 19;279(12):11051-64. Epub 2004 Jan 2.
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, Shah M, Christensen JG, Rosen N, Solit DB, Weiser MR.
Mol Cancer Ther. 2008 Nov;7(11):3499-508. Epub 2008 Oct 30.
Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1.
Lahusen T, Fereshteh M, Oh A, Wellstein A, Riegel AT.
Cancer Res. 2007 Aug 1;67(15):7256-65.
J Cell Physiol. 2010 Dec 7. [Epub ahead of print]
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on